Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

2.09

Mkt cap

40M

Volume

242K

High

2.40

P/E Ratio

-1.11

52-wk high

6.01

Low

2.08

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals, Inc. (NRXP) held its Q4 2024 earnings call on March 17, 2025. Key participants included Matthew Duffy, Jonathan Javitt, and Michael Abrams. The call featured questions from analysts such as Jason Kolbert, Thomas Shrader, and Vernon Bernardino.

Portfolio Pulse from

March 17, 2025 | 3:00 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has reported its Q4 and full-year 2024 financial results. The company is advancing its drug pipeline with NDAs for NRX-100 and NRX-101, targeting FDA approval by 2025. It has also accepted potential licensing terms for NRX-100 and is working on regulatory actions regarding ketamine formulations.

Portfolio Pulse from

March 17, 2025 | 12:15 pm

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its Q4 and full year 2024 financial results on March 17, 2025, before the market opens. A conference call will follow at 8:30am ET.

Portfolio Pulse from

March 12, 2025 | 12:15 pm

NRx Pharmaceuticals is set to release its Q4 earnings, with expectations of updates on its pipeline candidates for central nervous system disorders.

Portfolio Pulse from

March 03, 2025 | 6:15 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics will present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025. They will also participate in the 2025 BIO CEO & Investor Conference in New York from February 10-12.

Portfolio Pulse from

February 06, 2025 | 1:15 pm

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has regained compliance with Nasdaq's minimum market value of listed securities requirement, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from

January 21, 2025 | 1:15 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has appointed Michael Taylor to its Board of Directors and Anita Nunes as a Board Observer. Nunes will also be appointed Director of HOPE Therapeutics, Inc., a subsidiary of NRx.

Portfolio Pulse from

January 15, 2025 | 1:15 pm

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, highlighted a CNN program featuring Dr. David Feifel discussing ketamine. Kadima Neuropsychiatry Institute, founded by Dr. Feifel, is set to become HOPE's flagship clinic upon acquisition closure.

Portfolio Pulse from

January 14, 2025 | 1:15 pm

NRx Pharmaceuticals, Inc. has applied to NASDAQ to uplist from the NASDAQ Capital Market to the NASDAQ Global Market, which could improve shareholder liquidity. The company currently has 15.7 million shares outstanding.

Portfolio Pulse from

January 13, 2025 | 1:15 pm

HOPE Therapeutics and NRx Pharmaceuticals will present a keynote on combined interventional treatment for suicidal depression and PTSD at the Neuroscience Innovation Forum. NRx has filed an NDA for NRX-100, and HOPE plans acquisitions to expand its psychiatry clinics.

Portfolio Pulse from

January 07, 2025 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.